Teva-Handok wins approval for anti-asthma injection < Pharma < Article - KBR
Dosing and Administration
761033Orig1s000
These highlights do not include all the information needed to use CINQAIR safely and effectively. See full prescribing information for CINQAIR.CINQAIR® (reslizumab) injection, for intravenous useInitial U.S. Approval: 2016
Attachment: Product Information: Reslizumab
Teva's Asthma Segment: What Could Boost Its Revenues in 2016?
Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
Teva filled Biologics License Application for reslizumab Archives • NCK Pharma
Reslizumab
Older Patients with Asthma Do Well with Reslizumab | RT
Teva announces FDA approval for asthma injection, Cinqair | Pharmafile
Cinqair (reslizumab): Basics, Side Effects & Reviews
Israeli Pharma gets FDA Approval for Asthma Antibody
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
CINQAIR® (reslizumab) Injection – About Asthma Control
Teva's Severe Asthma Therapy Reslizumab Now Approved in Europe | RT
A Guide to the PRESCRIPTION AND SERVICE REQUEST FORM FOR CINQAIR® ( reslizumab) Injection
FDA accepts Biological License Application for reslizumab
Teva Announces EMA Validation of Reslizumab Marketing Authorization Application
NICE changes mind and backs new drug for severe asthma | Nursing Times
Chest Medicine Made Easy-Dr Deepu: FDA approves Injectable drug for uncontrolled Asthma
Reslizumab Reslizumab (Teva) | Bioz | Ratings For Life-Science Research
Teva files MAA for asthma treatment reslizumab
Teva's Asthma Therapy Reslizumab Fails in Late-Stage Studies
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Teva Reports Two Successful Phase III Studies For Reslizumab In Asthma
